Wednesday, October 31st
VSUR, SPNG, SDVI, EBFD, EPLI, UVSE, HSXI
ROTB, ANSR, MVBY, NMSS, HNAB, NPSP, NVAX, TPLM
Our Stocks to Watch today include Vsurance Inc. (OTCBB:
Spongetech Delivery Systems (OTCBB: SPNG), Signature Devices, Inc. (OTC: SDVI), eBenefits Direct (OTC: EBFD), The Employer Inc. (OTC: EPLI), Universal Energy Corp.
(OTCBB: UVSE), HealthSonix, Inc. (OTC: HSXI), Rotoblock Corporation (OTCBB: ROTB), Answerthink (NASD: ANSR), My Vintage Baby, Inc. (OTC: MVBY), NMS Communications Corp. (NASD: NMSS), Hana Biosciences (NASD: HNAB), NPS Pharmaceuticals, Inc. (NASD: NPSP), Novavax, Inc. (NASD: NVAX) and Triangle Petroleum Corporation (OTCBB: TPLM).
VSURANCE INC (OTCBB: VSUR)
Vsurance is a leading provider of pet health insurance and other pet health-related services in the United States. Programs include its Get HIP™ Pet Health Insurance for Pets program, the most comprehensive full-coverage pet health insurance plan in the industry. Vsurance provides pet and horse resource centers through the Internet including VetpetMD™, Spot the Pet™, and Purrfect Pet Club™. Programs include life, liability, and health insurance for pets, horses, and other companion animals.
31 - Vsurance Announces Winner of Cesar Milan Live in San Antonio Texas on December 8, 2007
VIP Meet & Greet / Front Row Seats / Free Vsurance Pet Policy Included
Vsurance, Inc. (OTCBB: VSUR), a leading provider of pet health insurance, announced the official winner of the Company sponsored event to see Cesar Milan Live, a special live program featuring the world-renowned dog behaviorist Cesar Milan.
On October 11, Vsurance offered pet lovers the chance to meet Cesar Milan, star of the Emmy Nominated hit TV Show Dog Whisperer on the National Geographic Channel. Vsurance offered pet lovers across the nation the opportunity to win two VIP tickets to Cesar Milan Live.
Vsurance is pleased to announce the lucky winner of the Cesar Milan contest is Mr. Erick Markey of Salt Lake City, Utah.
“I am very excited to win this amazing opportunity to see Cesar Milan up close and in person for the very first time,” said Mr. Markey. “I look forward to seeing his magical wisdom about dogs and dog psychology in action. I am extremely grateful to Vsurance, Inc. for this exciting opportunity, and I am even more grateful to the pet insurance company for the complimentary health insurance policy for my beloved pet. If my dog Maxx could speak, I’m sure she would thank Vsurance too!”
Mr. Markey’s will be in the front row of the exciting Cesar Milan Live Seminar at the Majestic Theatre San Antonio, Texas on Saturday, December 8, 2007 at 2:00 PM. He will also be awarded the chance for a one-on-one meet and greet with the celebrity dog behaviorist and trainer, including an exclusive photo opportunity with Mr. Markey and Maxx. In addition, Mr. Markey will receive complimentary gifts provided by Vsurance, as well as a free membership to the Vsurance Club, including one year's free Vsurance Protect 1 Accident and Injury Coverage.
At the Cesar Milan Live Seminar, Mr. Markey and other attendees will be immersed in Cesar's world for three compelling hours, as the best-selling author of Cesar's Way reveals his secrets to happier, healthier relationships between humans and their canine companions.
Specifically, the Seminar on December 8, 2007 will focus on:
- To recognize the "animal" behavior in dogs.
- How we humanize dogs and how this "people" behavior impacts the "dog" behavior.
- The different levels of energy and how they influence the dog's personality.
- What “dog fulfillment” is and how we can balance them by following simple guidelines.
- Cesar's leash techniques and when and where to apply them.
DELIVERY SYSTEMS (OTCBB: SPNG)
Systems is a development stage company
which designs, produces, markets and distributes cleaning
products for vehicular use utilizing patented technology
relating to sponges containing hydrophilic (liquid
absorbing) foam polyurethane matrices. The Company's
sponges are specially configured with an outer contact
layer and an inner matrix, which is loaded with specially
formulated soaps and wax that are released when the
sponge is applied to a surface with minimal pressure.
The Company's products are currently designed specifically
for vehicular cleaning use. However, the Company is
exploring the possibility of using its patented technology
for the development of sponges for other uses, including
for use with anti-bacterial, bath and kitchen soaps
for household uses, as well as for use as a children's
bath foam sponge.
SpongeTech Delivery Systems Issues Corporate Update on Company
SpongeTech Delivery Systems, Inc. (OTCBB: SPNG) CEO Michael Metter released the following letter to shareholders:
We have had an exciting year this year and have made a lot of progress moving our company from a development stage company into a production stage company. We started off 2007 with no sales backlog to speak of, and minimal sales outside of some legacy accounts that we had been servicing for a while. Since that time we have built up a sales backlog of more than $10.7 M and our online e-commerce sales have done very well. Below are a few more of our company's accomplishments for 2007.
Since the beginning of the year we have accomplished the following:
- Ramped up product manufacturing to build sufficient inventory to
service growing sales channels. We currently have around a million
units of our SpongeTech Car Wash & Wax Products in stock to service
- We launched a new company web site with e-commerce and online ordering
facilities. We have seen significant month over month growth in our web
site traffic and online sales and these sales are high margin sales.
- The company has accumulated more than $10.7 M in sales backlog which is scheduled to be shipped between Q4, 2007 and the end of Q3, 2008.
- During 2007 we have signed several new international product
distributors in Mexico, South America and Asia which have significant large orders in place for 2008 delivery.
- SpongeTech has participated in numerous Trade Shows in 2007 with
enthusiastic response for our products, and we are diligently working
to turn these show contacts into purchasing customers.
- During 2007 I have personally been a guest on investor talk shows, have
conducted phone interviews with a number of online IR outlets, and was
recently a guest on MoneyTV.net which has worldwide TV distribution.
- SpongeTech has ramped up marketing activities including conducting
numerous online sales promos this year which have resulted in many
incremental sales and a significant increase in web site traffic month
- We recently launched a new Children's Bath Product at a Las Vegas International Children's Product Show to enthusiastic response and the
company will start shipping that product in the very near future.
- SpongeTech also recently announced a new manufacturing partnership with
Rogers Foam Corporation who has manufacturing capabilities
strategically located throughout the world. Rogers will be bringing new
production online in Q1 2008.
- SpongeTech is working on finalizing our new infomercial and marketing
campaign with Incredible Discoveries. This new infomercial is scheduled
to debut very soon and is expected to generate projected orders in the
neighborhood of $19 M over the next 18 months.
- SpongeTech recently announced new free-standing retail point of sale
(POS) display units for their SpongeTech Car Care Delivery System
Products for the upcoming holiday season and should help the company
increase its holiday sales given that the company won't need to fight for space on retail store shelves during the holiday season.
Company Expectations for remainder of 2007 and 2008:
- SpongeTech will continue to grow its online sales and marketing efforts
and will continue to upgrade its web site and online product sales and
fulfillment capabilities to facilitate more high-margin online sales.
- We expect to start shipping our new Children's Bath product soon which
will begin to open up new sales and distribution channels for the
company and should positively impact our sales numbers for 2008.
- We will aggressively continue to pursue new domestic and international
sales partners to open up new markets for our Car Care and Children's
Bath products around the world.
- We will continue to develop new products to attack new vertical market
segments suited for our product technology and thus open new markets
and sales channels for SpongeTech products.
- We will continue to raise the visibility of our company and stock
within the investor community through frequent communications to investors through press releases, executive interviews, online talk
shows, and participation in investor conferences.
- We plan to attend more market related trade shows in 2008 to attract
new customers and increase visibility of SpongeTech and our products to
- SpongeTech will continue to enhance its manufacturing capabilities and
find ways to reduce product costs through production volume,
SpongeTech already has orders on the books which should drastically increase our gross revenues in 2008 over 2007 sales numbers, and should help us to turn the corner on company profitability. We will continue to be conservative in the growth of our overhead costs while still trying to find new and innovative ways to increase our marketing presence and grow our sales channels and volumes. We believe that we have just barely scratched the surface in opening new sales and distribution channels on a global basis, and as we bring on new distribution partners we believe our sales will continue to grow in significant ways.
SpongeTech has made a lot of progress in 2007, and we expect great things for our company in 2008, and beyond. We are committed to continuing to keep SpongeTech investors up to date on what is going on with the company and we will put out relevant press releases on an ongoing and timely basis.
We want to thank SpongeTech investors for sticking with us this year and we will do our best to help reward SpongeTech investor's patronage and loyalty with our efforts moving into 2008, and beyond.
Michael Metter, CEO
For more information please contact Investor Relations at
1-877- SPONGE T or visit the company website at: www.spongetech.com.
SIGNATURE DEVICES (OTC: SDVI)
Signature Devices, Inc. engages in the development, manufacture, and sale of information technology products in the United States. The company creates, develops, and publishes 3-D interactive games for consoles and personal computers. It also publishes software for video games and commercial products. The company publishes games for consoles, such as GBA, XBox360, and Playstation. In addition, the company provides consulting for information technology, including computer systems, software, and electronic products. It offers a platform for hardware, embedded systems development, and image generation technology, which can be used in films, videogames, and the military. Further, the company develops customized 3D identities, including lighting, shading, artificial intelligence, and animation systems. Signature Devices was founded in 2002 and is headquartered in Redwood City, California.
31 - Graffiti Entertainment and Studio Archcraft Team Up for Real Time Tactical Combat RPG on Nintendo's DS System
Leading video games publisher and developer Signature Devices, Inc. (www.signaturedevices.com) (OTC: SDVI) and their wholly-owned video game development and publishing subsidiary Graffiti Entertainment, LLC (www.GraffitiEntertainment.com), announced that they have signed an agreement with Studio Archcraft to publish their title "Project Exile," a real time tactical combat Role Playing Game (RPG) for the Nintendo DS. Graffiti Entertainment is planning to have the game on shelves in February of 2008.
"Project Exile is a fantastic Japanese style RPG. With over 50 hours of fun game play and stunning graphics, RPG fans will really enjoy this game. We are very excited to add this RPG to our growing list of published products," said Kenneth Hurley, CEO of both Signature Devices and Graffiti Entertainment.
Features that are unique to Project Exile for NINTENDO DS:
Beautiful and vivid environments create a realistic yet imaginative landscape filled with attractive and detailed scenery. There are complex worlds full of realistic characters struggling for control of their inner powers. Dark secrets and powerful plot twists fill an epic tale with imagination and life. The player controls a team of eight fully developed playable characters armed with over 100 different abilities, skills and combos, as they progress through a rich, colorful world, filled with magic and adventure.
Project Exile will ship in two languages, English and French, with four more languages to follow: Spanish, German, Italian and Japanese.
About Studio Archcraft:
Studio Archcraft is an independent game development studio that was founded in 2001 by Pierre-Yves Leclerc, Maya Anderson, Vincent Dehaut and Eunice Chou and is based in Montreal, Quebec, Canada with members from the U.S., the UK, Japan and Germany.
Nintendo and Nintendo DS are trademarks of Nintendo.
EBENEFITSDIRECT (OTC: EBFD)
eBenefits Direct, Inc. is a nationwide leader in the direct marketing and distribution of a wide range of health and life insurance products to individuals, families and groups. By utilization of its many call centers across the country it enables an individual to efficiently purchase health and life insurance as well as medical and discount service programs. The company has revolutionized the way health and life insurance has historically been sold. eBenefits Direct, Inc.'s approach is through many mass distribution areas such call centers, the internet and massive lead generation programs.
31 - eBenefits Direct, Inc. Forms Alliance With ABG
eBenefits (OTC: EBFD) Direct marketing director, Harold Halkstein, announced the company has established an alliance with ABG, a nationwide association of business owners and individuals that offers various insurance coverages to its members; its membership is available in all 50 states.
The insurance that will be offered include cancer and accident indemnity policies as well as disability income, long term care, life, dental and health insurance from major insurers. These insurers, in some cases, have for the first time agreed to offer their products nationwide through the internet and call centers for association members.
In announcing this alliance, both eBenefits Direct and ABG realize that various insurance coverages are not available directly to individuals, but rather only to employees of companies and to association members. Therefore both eBenefits Direct and ABG anticipate exceptional growth from this new relationship. Members of the ABG Association will be able to sign-up for insurance on the eBenefits Direct website, http://www.ebenefitsdirect.com, and they will have their own sign-in page exclusive to the members of this association.
Employer Inc. (OTC: EPLI)
The Employer Inc. is
an employer/job seeker human resource service company
focused on a variety of industries. The company provides
recruitment and job placement services in the professional,
management, clerical, administrative, service and
industrial markets. Its unique scientifically based
services, online and offline include job screening,
recruiting, and job matching to employer job requirements.
These unique services feature job seekers profiling,
three levels of background screening, customized personnel
management reports, job profiling, job analysis and
descriptions. Additional services include turnover
tracking and analysis, opinion surveys exit interviews
and follow-up issue analysis. A mainstay of The Employers
Inc. program is its employee/ employer benefits package
featuring an advanced electronic pay card system,
a community based Discount Payment Card including
health, vision, and dental programs. The Discount
Payment Card features over 15 other frequently used
community services for the entire family.
Strategic Alliance Associates provides loss prevention,
safety training, compensation program design, management
development, and pre-employment, skills testing assessments.
Online personal training and education programs providing
job seekers success tips and techniques ranging, from
interviewing skills, to dressing for the most positive
impact on employers.
University Affiliate Projects for research and development
features new products and services designed to keep
The Employer at the cutting edge of the ever changing
employer/job seeker requirements and expectations.
The Employer Inc., being at its
most pivotal point in their business endeavors to
date, is a tremendous value. The anticipation is that
through the growth of the business, and penetration
strategy to capitalize on the potential of the untapped
marketplace, that the management will be able to create
a very large, successful, and well branded company.
30 - The Employer, Inc. Exceeds Two Million Career Opportunities Profiled On Portal
The Employer Boasts the Availability of Employment Opportunities in Excess of Over Two Million Derived From More Than 1,000 of the Nation's Leading Job Listing Sites
The Employer, Inc. (OTC: EPLI), a human resources company that provides unique, technology-enhanced recruitment and job placement services, announced that the Company's Virtual Employment Portal has reportedly over two million employment opportunities currently posted and available to job seekers Nationwide.
The Employer, Inc. is a growing virtual employment portal that provides recruiting and job placement services in the professional, management, clerical, administrative, services and industrial markets. By accumulating opportunities through scouring the World Wide Web for listings, the portal can deliver a valuable service to a network of employers in the market for job seekers, and qualified prospective employees to companies seeking good human resources.
The Portal provides a distinct advantage to job seekers by providing a platform that will enable them to find as many listings at a single website as the alternative of visiting over a thousand websites individually. Employers also benefit from listing with The Employer because their employment listings are launched to over 100 additional sites at no additional cost for unparalleled exposure.
Employers with featured opportunities on the site include: Bank of America, Wachovia, Coca-Cola Enterprises, Procter & Gamble, Walt Disney World, Wyndham Worldwide, Florida Hospital, Aetna, Philip Morris USA, The New AT&T, AIG, JP Morgan, among numerous other prominent organizations. There are also thousands of small to medium sized companies listed on the website that are providing employment opportunities to job seekers across the country.
Management estimates that the Company's growth strategy will expose approximately 25 million new potential clients to the company's innovative and expanding service, and ultimately create a niche in the marketplace that The Employer's virtual employment portal is exclusively set up to service.
"We are capitalizing on technology that can deliver an exceptionally comprehensive service, which is quickly evolving to be second to none. We live in a day and age that should be offering more in the employment industry than what's currently being delivered by competitive industry leaders. We intend to monopolize this market, and simultaneously create an effective resource for job seekers and employers, and a profitable environment for partners and shareholders," stated Sam Rodenberger, President of The Employer, Inc.
ENERGY CORP (OTCBB: UVSE)
Universal Energy Corp. is an energy company engaged in the acquisition
and development of crude oil and natural gas leases
in the United States and Canada. We pursue oil and
gas prospects in partnership with oil and gas companies
with exploration, development and production expertise.
Our prospect areas consist of lands in Alberta, Canada,
Louisiana and Texas. Visit www.universalenergycorp.info for more details.
31 - Universal Energy Corp. Announces Successful Drilling Program at its Lake Campo Prospect
Universal Energy Corp. (OTCBB: UVSE) released the following update on its Lake Campo prospect. In an announcement last week, Universal Energy Corp. announced that the analysis of daily reports from the Lake Campo prospect was providing an excellent indication as to the overall success of the prospect.
During the past few days, drilling operations reached the target depth of the well and an analysis of the well log was performed. The well log analysis showed 46 feet of gas pay throughout 4 sections of the well. Based on this analysis, the company and its well partners have elected to install production casing for the well. Lake Campo will be Universal Energy Corp.'s third commercial discovery of oil and gas within the past eight weeks.
"Three for three is not bad," commented Billy Raley, Universal Energy Corp. CEO when asked about the recent drilling success at the company's Amberjack, Caviar #1 and Lake Campo prospects. Raley continued, "Our prospect portfolio is proving its merit with each turn of the drill bit."
HEALTHSONIX (OTC: HSXI)
in morning trading"
HealthSonix, Inc. is a publicly-traded medical technology company, engaged in the development, manufacture, and sale of proprietary medical products and biotechnologies that provide pain relief and muscle stimulation for people with osteoarthritis, rheumatoid arthritis, fibromyalgia, and musculoskeletal conditions related to muscle injuries -- essentially medical conditions where acute and chronic pain, muscle stiffness, poor circulation, and diminishing flexibility are among the underlying symptoms. The company's integrated portfolio of Food and Drug Administration ("FDA") registered products currently in the commercial marketplace includes: enSonix@home; AquaSonix Therapy; enSonixPro; and ZingiberRx pain relieving cream.
HealthSonix Announces Expansion in Florida
HealthSonix, Inc. (OTC: HSXI) (Frankfurt:H7S.F) announced that it is has selected a prestigious medical center in Boca Raton, Florida, for the first location of its specialty Arthritis Treatment Centers of America [ATCA]. The grand opening is scheduled for the spring of 2008.
The Arthritis Treatment Centers utilize the most advanced, non-invasive medical technologies and combine them with the best of the established therapies to reduce and even eliminate arthritis pain and restore joint mobility. The current treatment programs have exceptional success rates: 4 out of 5 patients report significant pain reduction in addition to greater mobility, more energy, and improved sleep.
ATCA follows the guidelines published by the American College of Rheumatology which recommend the use of nonpharmacologic therapies as a first line of defense. ATCA practices an integrated approach to arthritis care and the Centers are staffed with healthcare professionals from many of the medical disciplines required to address arthritis: Physical and Occupational Therapy; Rheumatology Rehabilitation; Kinesiology; Psychology; and Nutrition.
"In our facilities we promote wellness through a warm and welcoming environment. Our patients have helped us design many of the amenities that make each visit a pleasant and rewarding experience," stated Dieter D. Doederlein, Vice President of Corporate Development at HealthSonix. "With this new state of the art facility we'll be able to effectively service patients in the Palm Beach County. The new center will also double as a showcase facility and a training center for the South East United States. Arthritis is a number one source of pain in the world and population profile in South East Florida fits with the type of demographics we target with our treatments," added Doederlein.
ROTOBLOCK CORP (OTCBB: ROTB)
in morning trading"
Rotoblock Corporation engages in the development and licensing of oscillating piston engine (OPE). It holds an option entitling to acquire the rights, title, and interest in OPE for use in driving a ducted fans, electrical charging systems, pumping systems, and helicopters. The company was founded in 2003 and is headquartered in Santa Rosa, California.
US-China Entrepreneur Named Rotoblock CEO
Rotoblock Corporation (OTCBB: ROTB), developer of an advanced Oscillating Piston Engine (OPE) technology, announced that Chinese-American entrepreneur Mr. Liu Chien-Chih has agreed to join as Chief Executive Officer.
Mr. Liu has over 15 years' experience in international trade, marketing and manufacturing. Born in Taiwan, Mr. Liu immigrated with his family to the USA at the age of 10. Fluent in English and several Chinese dialects, Mr. Liu earned a Bachelor of Science Degree in Chemical Engineering from the University of California at Berkeley. Since that time he has spent much of his career capitalizing on new ideas and technologies and sees an opportunity with Rotoblock.
"China is going through an industrial revolution and I see the market for small engines and advanced drive train development exploding with new technologies and economic growth," said Mr. Liu. "Rotoblock will explore the commercialization of the oscillating piston engine in China as well as pursue new opportunities for developing new products, commercializing the brand and distributing it worldwide."
Prior to joining Rotoblock, Mr. Liu served for more than five years as a Vice President for Tianyi Group of Nanjing, China, a multi-billion dollar conglomerate involved in the manufacturing of automotive components and commercial equipment with over 10 subsidiaries. Mr. Liu served a variety of roles with Tianyi Group, which operates several factories in China. He managed Tianyi's extensive portfolio of real estate developments and other investments. He also managed the subsidiary Hikom/Goettel, one of the largest manufacturers of air conditioning in China. Hikom is the sole sponsor of the Shanghai Sharks Professional Basketball team, for which Yao Ming played before being recruited to the NBA.
"I am committed to devoting 100 percent of my time to growing Rotoblock," said Mr. Liu. "With the experience and relationships developed with Tianyi Group, I believe I can take Rotoblock to new levels."
"I congratulate Mr. Liu on his new venture and wish him nothing but success," said Tianyi Group Chairman and CEO Mr. Jiang Guobei. "I have every confidence in his ability to grow this company. Mr. Liu has a keen eye for new opportunities and taking them to completion and he will be missed here at Tianyi Group."
ANSWERTHINK (NASD: ANSR)
in morning trading"
Answerthink, Inc. operates as a business and technology consulting company. The company offers a range of services, including advisory programs, benchmarking, business transformation, working capital, best practice research, business applications, and business intelligence implementation. It serves automotive, consumer goods, financial services, technology, life sciences, manufacturing, media and entertainment, retail, telecommunications, utilities, and transportation industries. The company was founded in 1991 and is based in Miami, Florida.
Answerthink earnings up
Thanks largely to its Hackett Group consultancy subsidiary, Answerthink's (NASD: ANSR) third quarter earnings were up over seven cents a share. The Miami-based firm said it earned $3.6 million, or eight cents a share, on revenue of $46.7 million. For the same quarter last year, the company reported earnings of $473,000, or a penny a share, on revenue of $43.5 million.
MY VINTAGE BABY (OTC: MVBY)
in morning trading"
My Vintage Baby, a newly publicly traded entity, operates in the $30.6 Billion Dollar children's apparel industry offering some of the world's most sought after unique-luxury children's clothing and accessories. Founded in 2001, MVBY has experienced tremendous growth as its unique children's apparel line has been recognized by major department stores and private retailers across the nation. My Vintage Baby is recognized as "a piece of yesterday for the hip child of today." What makes My Vintage Baby clothing and accessories different is that each item has vintage materials and is one-of-a-kind. My Vintage Baby embellishes with old feed sacks, hankies, chenille, aprons, and tablecloths to embellish the clothing, creating truly unique designs. Its garments are designed with a stunning combination of trendy/new and hand selected vintage materials resulting in one of a kind piece, each with its own nostalgic yet stylish look. The vision is to make each garment as unique as the children who wear them. A My Vintage Baby outfit turns ordinary days into special and memorable events for both child and parent.
My Vintage Baby (MVBY) Propels Past Previous Years Revenues By 31 Percent as It Reports Record Sales Figures For Its 2008 Spring Collection
My Vintage Baby, Inc. (OTC: MVBY), a unique children's apparel company, announced that its new 2008 Spring Fashion Line has shown remarkable sales results as it propels past Spring 2007 sales by 31 percent.
As purchase orders continue to be received, MVBY reports nearly $700k in sales resulting from its efforts at the children’s fashion markets for Dallas, TX, Atlanta, GA and New York with purchase orders from some of the world’s most prominent retailers, immediately offering the MVBY 2008 Spring Line for retail purchase.
“We have been working markets and presenting the new line around the clock. We hosted Sip and See events in both Atlanta and Dallas during market with models previewing our clothing. This was a great success with our retailers generating new business. Our Spring 2008 purchase orders received to date have exceeded Spring 2007 by 31% and orders are still being submitted daily. Our new line has truly shown to be a success and we could not be more pleased,” stated Jessica Wiswall, CEO of My Vintage Baby, Inc.
In addition, MVBY just celebrated its Design Excellence Earnie Award in a fashion show hosted by Earnshaw’s, the leading children’s apparel trade magazine and ceremony in NY at ENK Monday, October 15th. The event, which was co-sponsored this year by the ENK Children’s Club trade market, recognized retailers’ picks for superior design in the children’s wear market. The magazine placed a spotlight on this year’s winning manufacturers, including MVBY, with a festive event held “Under the Big Top,” which included a runway show of mini models decked out for a day at the circus. As previously stated, MVBY was awarded the prestigious Earnie Award for 2T-6x Sportswear Design Excellence.
NMS COMMUNICATIONS (NASD: NMSS)
in morning trading"
NMS Communications Corporation provides technologies, platforms, and systems to wireless and wireline telecommunications operators, network equipment, and application providers worldwide. It operates in three segments: Platform Solutions, Mobile Applications, and Network Infrastructure. The Platform Solutions segment provides Open Access products for developing and deploying voice, video, and data applications and services, such as Internet protocol (IP) conferencing, speech activated services, music applications, and mobile video; Vision family of media servers and gateways to develop converged multimedia applications; and Voice Quality Systems, which include Studio Sound software that creates listening environment for all parties in a wireless telephone conversation. The Mobile Applications segment offers MyCaller Ringback, which enables mobile subscribers to select original recordings of music, sounds, and voices for callers to hear in place of the conventional ringback tone until the call is answered; and Mobile Place that combines various applications with subscriber and content management system. The Network Infrastructure segment offers AccessGate, a wireless backhaul optimization system. The company also provides a range of technical and operational support, system integration, and professional services. NMS Communications sells its products through direct sales force, channel partners, and system integrator partners. The company was founded in 1983 and is headquartered in Framingham, Massachusetts.
NMS Communications Announces Financial Results for the Third Quarter Ended September 30, 2007
NMS Communications Corp. (NASD: NMSS), a leading provider of applications and platforms for value-added services in mobile telecommunications announced financial results for the third quarter ended September 30, 2007.
Total revenues for the third quarter of 2007 were $23.2 million, an increase of 11% compared to $20.8 million for the corresponding quarter in 2006 and 8% compared to $21.4 million for the second quarter of 2007. GAAP net loss for the third quarter was $1.5 million, or $(0.03) per share, an improvement compared to a GAAP net loss of $5.9 million, or $(0.12) per share, for the third quarter of 2006.
Non-GAAP net income was $14,000, or $0.00 per share, for the third quarter of 2007, an improvement compared to a non-GAAP net loss of $4.1 million, or $(0.09) per share, in the third quarter of 2006. The non-GAAP net loss for the third quarter of 2007 excludes $1.5 million in non-cash charges, comprised of $1.2 million of stock-based compensation expense and $0.3 million of amortization of acquired intangible assets.
The cash, cash equivalents and marketable securities balances totaled $28.3 million on September 30, 2007, compared to $30.4 million at the end of the previous quarter.
"Our results for the third quarter were in-line to slightly better than our expectations. The quarter was highlighted by a return to revenue growth, both sequentially and on a year-over-year basis. Combined with strong gross margins and continued tight spending controls, we are on track to achieve our second half target of returning to break-even non-GAAP profitability. While we have made significant progress toward improving our financial profile over the past year, we believe there is still substantial room for improvement,” said Bob Schechter, NMS Communications’ Chairman and CEO.
"Our Communications Platforms (CP) business experienced solid sequential and year-over-year growth for the first time in over a year. Looking ahead, we believe that our CP business is well positioned to deliver modest growth, driven by new design wins, mobile video and speech-enabled applications, especially in Asia where subscriber growth is forecast to remain very strong. In addition, our CP business continued to generate strong gross margins and contribution margin exceeding 20%, which has provided the capital to invest in our high growth Mobile Applications business,” Schechter continued.
“We continue to be very excited about our Mobile Applications business, which grew over 50% year-over-year in the third quarter. The underlying drivers to the Ringback market remain robust, and we are on track to triple the number of subscribers using our market leading MyCaller™ solution for the second consecutive year. These trends are particularly exciting as we begin to transition our business to a managed services model, which we believe will maximize our revenue opportunity, visibility and predictability.
"AccessGate ™, which is the smallest component to our business, more than doubled sequentially and on a year-over-year basis. Growth was driven by strong demand, particularly in Latin America. With a solid pipeline of opportunities, we believe AccessGate is well positioned to finish the year with strong annual growth.
In summary, we are pleased with our progress this quarter and recognize there is a good deal more to be done. We continue to see the Mobile Applications market as an area for strategic expansion and believe our ongoing shift to managed services will enable us to offer our customers an end-to-end service platform and provide NMS a more repeatable and predictable revenue stream. Our focus on the Communications Platform group is paying off, and we believe that the erosion in the low end of our customer base, which has been a primary contributor to this segment’s decline in the past year, has largely run its course. We remain highly focused on continuing to improve our financial performance in order to drive long-term shareholder value," Schechter concluded.
We currently expect growth in Q4 to be positive on a year-over-year basis and leading to revenue that is up modestly from what was delivered in the recently completed Q3. The timing of revenue recognition in our Mobile Applications business can add an element of variability in quarterly performance. From a profitability perspective, we continue to expect to operate at about break-even on a non-GAAP basis in Q4 based on modest growth in revenues, gross margin levels a bit below the unusually strong performance in Q3, and continued tight expense controls.
HANA BIOSCIENCES (NASD: HNAB)
in morning trading"
Hana Biosciences, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and commercialization of products for advance cancer care in the United States. It develops a pipeline of oncology based drug candidates, including therapeutic product candidates designed to destroy cancer cells; and supportive care product candidates to treat or prevent side effects caused by therapeutic cancer treatments. The company's therapeutic products include Marqibo, an anti-cancer drug vincristine for the treatment of nonHodgkin's lymphoma and acute lymphoblastic leukemia; Talvesta, a novel anti-folate drug product candidate used as a chemotherapy agent in the treatment of various solid tumors and hematological malignancies, including nonsmall cell lung cancer (NSCLC) and other solid tumors; Alocrest, an anticancer drug vinorelbine for the treatment of solid tumors, such as NSCLC and breast cancer; and Sphingosome encapsulated topotecan for the treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy, and small cell lung cancer sensitive disease after failure of first-line chemotherapy. Hana's supportive care products comprise Zensana, which is developed to alleviate chemotherapy- and radiation-induced, and post-operative nausea and vomiting; and Menadione for the prevention and treatment of skin rash associated with the use of epidermal growth factor receptor. The company was founded in 2000 and is headquartered in South San Francisco, California.
Hana Biosciences Receives $30 Million Funding Commitment from Deerfield Management
Hana Biosciences (NASD: HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, announced that Deerfield Management, a leading healthcare investment fund, has committed up to $30 million in funding, including $7.5 million upfront, to assist with financing the development of the company’s pipeline of product candidates. Hana Biosciences is currently advancing two anti-cancer compounds through clinical trials, with additional therapeutic product candidates and an oncology supportive care product in late-stage preclinical development.
“This financing commitment provides us the resources to advance our pipeline of product candidates through the next stages of development and potential value formation,” said Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. “We are aligned with respect to Hana’s pipeline potential, development strategy and future goals. We are focused on product development and dedicated to the steady growth of the company over the next several years.”
"In addition to Hana's clinical-stage programs, we believe that menadione represents an exciting opportunity in the treatment of one of the most common adverse events of modern biologic therapy," said Howard Furst, M.D., a Partner at Deerfield Management. "We believe that this type of financing vehicle will work well for the company in that it provides funds as needed, and recognizes concrete program milestones and development progress, while creating minimal dilution relative to the company's market capitalization and resource requirements."
Deerfield's commitment of up to $30 million is in the form of an interest-bearing loan that can be drawn down at pre-determined intervals over a three-year period. Hana will immediately draw down $7.5 million. The availability of one-third of the $30 million is subject to the achievement of specific milestones associated with the development of the company’s Marqibo and menadione product candidates. The outstanding principal and interest, which accrues at the rate of 9.85 percent per annum, is due by October 2013. Deerfield received a one-time 3.5 percent cash commitment fee and six-year warrants to purchase approximately 5.2 million shares of Hana’s common stock upon execution of the loan agreement at an exercise price of $1.31 per share, the closing bid price on October 30, 2007. Additional warrants will be issuable if the company draws down the portion of the loan facility subject to milestones. The warrants are subject to certain anti-dilution features.
“We are pleased that one of our top current shareholders has expressed its confidence in our company and assets with this financing. Hana has reached an important juncture in the maturation of our clinical-stage programs, and we believe this financing vehicle offers access to funds while addressing the best interests of our current shareholders,” added John Iparraguirre, Vice President, Chief Financial Officer of Hana Biosciences.
About Hana Biosciences’ Oncology Pipeline
Hana Biosciences’ oncology pipeline consists of four therapeutics and one supportive care compound. The company is currently conducting a registration-enabling program for its lead compound, Marqibo® (vincristine sulfate injection, OPTISOME™), in relapsed acute lymphoblastic leukemia (ALL). Hana plans to advance Marqibo into uveal melanoma this year, and expects to initiate a Phase 3 clinical trial in first-line ALL in 2008. The company also has an ongoing Phase 1 clinical trial with Alocrest™ (vinorelbine tartrate injection, OPTISOME™) and plans to commence a Phase 1 clinical trial with Brakiva™ (topotecan hydrochloride injection, OPTISOME™) this year. For Menadione, Hana’s supportive care product candidate, the company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration by the end of the year.
NPS PHARMACEUTICALS (NASD: NPSP)
in morning trading"
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic small molecule drugs and recombinant proteins. Its products portfolio of approved drugs and product candidates are primarily used for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. The company's products for bone and mineral disorders include PREOS for the treatment of osteoporosis; Calcilytic Compounds, which are under Phase I clinical trial for the treatment of osteoporosis; and Cinacalcet HCl that completed Phase II clinical trial for the treatment of hypoparathyroidism. It also offers Teduglutide, which is under Phase III clinical trial for the treatment of short bowel syndrome and under Phase II clinical trial for the treatment of Crohn's disease; and glycine reuptake inhibitors that are in Phase I clinical trial for the treatment of schizophrenia and dementia. The company was founded in 1986 and is headquartered in Parsippany, New Jersey.
31 - Nycomed Confirms Commitment to GATTEX(TM) Partnership; NPS to Receive $25 Million Payment
NPS Pharmaceuticals, Inc. (NASD: NPSP) announced that Nycomed, after an in-depth review of the results from the recently completed Phase 3 study in Short Bowel Syndrome, has confirmed its intention to proceed with the development and commercialization of GATTEX(TM) (teduglutide) outside North America. Under the terms of the partnership agreement signed in September, Nycomed will pay NPS the $25 million up-front payment balance due and receive licensing rights to develop and commercialize GATTEX outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders. NPS will retain the right to develop and commercialize GATTEX in North America.
In addition to the $35 million total up-front payment, NPS has the potential to earn up to $150 million in payments related to the attainment of certain regulatory milestones for the SBS indication, the successful development of new indications and the achievement of sales-based milestones. Additionally, the agreement provides for double-digit royalties on GATTEX sales in the Nycomed territories. The agreement also provides for development cost-sharing on a 50:50 basis for indications which are pursued jointly.
Nycomed CEO Hakan Bjorklund stated: "We look forward to working with NPS to develop and commercialize GATTEX as a new therapy for SBS and potentially for other serious gastrointestinal conditions. We believe GATTEX will be an important addition to our product pipeline and expect it to complement our development and marketing capabilities in the gastroenterology field."
NPS president and CEO Dr. Tony Coles stated: "We are pleased that our partner, Nycomed, has confirmed its commitment to the development of GATTEX outside North America based upon the results of the recently completed Phase 3 SBS study. We greatly appreciate their vote of confidence in GATTEX and look forward to discussing the study results with the FDA so we can proceed as rapidly as possible with the next steps required to obtain regulatory approval of the drug in the United States. With our recent successful financing and asset monetization activities and Nycomed's commitment to GATTEX, NPS is now in an excellent position to complete the registration of GATTEX in SBS and pursue its development in multiple indications."
A potential first-in-class drug, GATTEX is a proprietary analog of naturally occurring human glucagon-like peptide 2 (GLP-2), a peptide secreted primarily in the distal intestine and involved in the regeneration and repair of the intestinal epithelium. In addition to its potential use in short bowel syndrome, NPS is also pursuing development of GATTEX as a possible treatment for chemotherapy-induced gastrointestinal mucositis in cancer patients and necrotizing enterocolitis in preterm infants.
NOVAVAX (NASD: NVAX)
in morning trading"
Novavax, Inc., a biopharmaceutical company, focuses on the development of vaccines for infectious diseases. The company, using its proprietary virus-like particle (VLP) and Novasome adjuvant technologies, develops vaccines against H5N1, H9N2, and other subtypes of avian influenza with pandemic potential; viral diseases; and human seasonal influenza. In addition, the company focuses on developing its VLP technology into vaccines for the prevention of HIV-1/AIDS and SARS. It has developed vaccines to prevent hepatitis caused by the Hepatitis E Virus, in collaboration with National Institute of Allergy and Infectious Disease; Walter Reed Army Institute for Research; GlaxoSmithKline Pharmaceuticals; and Wave Biotech. The company was founded in 1987 and is headquartered in Rockville, Maryland.
31 - Novavax upgraded by Oppenheimer
29 - Novavax CEO to Present at ACUMENBioFin's 9th Annual Healthcare Conference
Novavax, Inc. (NASD: NVAX) Chief Executive Officer Dr. Rahul Singhvi will present at ACUMENBioFin's 9th Annual Healthcare Conference at 10:55 am Eastern time on November 6, 2007 at the The New York Palace Hotel, New York City, the company announced.
Dr. Singhvi will provide an overview of the company's strategy, research and development progress and strategic partnerships. A link to an audio webcast of his presentation will be available at 10:55 am Eastern time on November 6, 2007 through the company's website, www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 30 days.
TRIANGLE PETROLEUM (OTCBB: TPLM)
in morning trading"
Triangle is an exploration company focused on emerging Canadian shale gas projects, the Fayetteville shale gas project in Arkansas and select conventional oil projects in the Rocky Mountains. An experienced team comprising technical and business skills has been formed to optimize the Company's opportunities through its operating subsidiaries, Triangle USA Petroleum Corporation in the United States and Elmworth Energy Corporation in Canada. For more information please visit www.trianglepetroleum.com.
31 - Triangle Finishes Drilling Second Well and Begins Seismic Program in Nova Scotia Shale Gas Project
Triangle Petroleum Corporation (the "Company" or "Triangle") (OTCBB: TPLM) is reports that the Company has now drilled two exploration test wells into the Horton Bluff shale formation on its 516,000 gross acre land position in Nova Scotia, Canada. The Horton Bluff shale formation is the exploration target for an unconventional gas resource play.
Drilling and Evaluation Programs
The following is a summary of the two wells drilled in the Company's Windsor Basin land block.
The first well, Kennetcook #1, reached a total depth of 4,390 feet and was rig released on September 15, 2007 after running casing to total depth. Kennetcook #1 is located 25 miles west of the community of Truro, Nova Scotia. This well was extensively cored over an interval of 1,150 feet. Advanced well log data was acquired on this well and the data is currently being integrated with the special core measurements performed by service companies with extensive unconventional shale gas expertise.
The second well, Kennetcook #2, reached a total depth of 6,350 feet and was rig released on October 13, 2007 after running casing to total depth. Kennetcook #2 is located approximately two miles north-west of Kennetcook #1 and was cored over an interval of 430 feet. Similar logging programs to Kennetcook #1 were performed and the integration with shale gas laboratory measurements is currently underway. Based upon preliminary log analysis, the primary shale zone in Kennetcook # 2 is approximately 500 feet thick.
Management has concluded that a comprehensive hydraulic fracture stimulation ("completion") program is warranted to assess the Horton Bluff deliverability. The Kennetcook #1 well will be completed first with the results of this operation used to guide the completion planning for Kennetcook #2.
A stimulation program design has moved forward based on favorable laboratory measurements of rock properties, gas content and fluid compatibility. A large, slick water fracture stimulation program is currently planned for late in the fourth quarter of 2007. Two frac water holding ponds have been constructed, each with the capacity to hold up to 2.5 million gallons of fluid. The program for the first frac single stage treatment is anticipated to be approximately 1 million gallons of slick water with 550,000 pounds of sand proppant volumes. Stimulations of this magnitude are in line with the current stimulations in the Barnett Shale of the Fort Worth Basin and the Fayetteville Shale of the Arkoma Basin.
An aggressive seismic program is being acquired: the 25 square mile 3-D program covers our initial target area over the Kennetcook wells and the 30 mile 2-D program extends to another favorable area of the land block. Shot hole drilling for both the 3-D and the 2-D programs has been completed and the data is being recorded. The acquisition and processing phase of the seismic program is expected to be finished by the end of November. Interpretation of this data is expected to occur within 60-90 days of the seismic program being completed. The first priority of the interpreted 3-D seismic program will be to select future well locations.
Gas marketing initiative
The development of on-shore gas production in Nova Scotia is in a very early phase. Triangle is currently in discussions with various marketing groups to communicate the aggressive exploration program initiatives that are in progress for the Windsor Basin of Nova Scotia. The gas currently marketed into the northeastern U.S. markets is being sold at a premium to other North American producing areas.
Ron Hietala, President of Triangle's operating subsidiaries, comments, "The Company is in a very exciting phase for testing this Canadian shale gas project. Within six months Triangle has moved forward with contracts being signed, followed by new drilling to proprietary seismic and now on to completion activities. The ability to operate and move forward under its own timetable has contributed significantly to where the Company is today."